# A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

> **NCT05984147** · PHASE1 · RECRUITING · sponsor: **Aurigene Discovery Technologies Limited** · enrollment: 40 (estimated)

## Conditions studied

- Relapsed Advanced Lymphomas

## Interventions

- **DRUG:** AUR108

## Key facts

- **NCT ID:** NCT05984147
- **Lead sponsor:** Aurigene Discovery Technologies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-19
- **Primary completion:** 2027-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984147, "A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05984147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*